Expert Interviews

Gregory Weiss, MD: Heart Failure Management in 2020

January 05, 2021

Gregory Weiss, MD, offers perspective on the diagnosis and management of heart failure during 2020.

Year in Review: Clinical Trials in Cardiology During COVID-19

January 01, 2021

Deepak Bhatt, MD, MPH, offers his perspective on how the ongoing pandemic has influenced clinical trials during 2020 and whether he thinks any changes will persist beyond the COVID-19 era.

Year in Review: Advances in Lipid Management During 2020

December 28, 2020

Practical Cardiology Advisory Board Member Brett Nowlan, MD, offers his perspective on the most important advances and topics in the field of lipidology from 2020.

The Importance of Educating Patients on Fish Oil Supplements vs Icosapent Ethyl

December 17, 2020

Learn more about the importance of educating patients on the differences between store-bought fish oil supplements and therapies derived from omega-3 such as icosapent ethyl (Vascepa).

Muthiah Vaduganathan, MD: Key Takeaways from Sotagliflozin Data

November 21, 2020

A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.

Deepak Bhatt, MD: STRENGTH, REDUCE-IT, and DHA

November 17, 2020

Deepak Bhatt, MD, MPH, offers his thoughts on the most important REDUCE-IT analyses released in 2020 and why he disagrees with the notion results of the STRENGTH trial somehow impact the use of icosapent ethyl in clinical settings.

Deepak Bhatt, MD: Sotagliflozin and Phase 3 Data from AHA 2020

November 17, 2020

Deepak Bhatt, MD, MPH, offers his thoughts on the results of SCORED and SOLOIST as well as diving deeper into the implications of the data for sotagliflozin and SGLT2 inhibitors moving forward.

John McMurray, MD: DAPA-CKD and Cardiorenal Protection

November 14, 2020

Professor John McMurray discusses DAPA-CKD and what insights it provides into the cardiorenal protection seen with dapagliflozin (Farxiga) use in the landmark trial.

Should Men and Women with HFpEF be Treated Differently?

November 14, 2020

Professor John McMurray offers insight into a discussion he led at AHA 2020 exploring the notion that treatment of men and women with heart failure with preserved ejection fraction should be approached differently.

George Bakris, MD: Improving SGLT2 Inhibitor Prescribing Practices

November 11, 2020

George Bakris, MD, discusses an AHA 2020 study that estimated the number of diabetics in the US that were considered eligible for receiving a prescription for an SGLT2 inhibitor.